These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 20600473)

  • 1. Fluvoxamine improved cognitive impairments in a patient with schizophrenia.
    Niitsu T; Shirayama Y; Fujisaki M; Hashimoto K; Iyo M
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Oct; 34(7):1345-6. PubMed ID: 20600473
    [No Abstract]   [Full Text] [Related]  

  • 2. Fluvoxamine as a sigma-1 receptor agonist improved cognitive impairments in a patient with schizophrenia.
    Iyo M; Shirayama Y; Watanabe H; Fujisaki M; Miyatake R; Fukami G; Shiina A; Nakazato M; Shiraishi T; Ookami T; Hashimoto K
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 May; 32(4):1072-3. PubMed ID: 18262707
    [No Abstract]   [Full Text] [Related]  

  • 3. A randomized, double-blind, placebo-controlled trial of fluvoxamine in patients with schizophrenia: a preliminary study.
    Niitsu T; Fujisaki M; Shiina A; Yoshida T; Hasegawa T; Kanahara N; Hashimoto T; Shiraishi T; Fukami G; Nakazato M; Shirayama Y; Hashimoto K; Iyo M
    J Clin Psychopharmacol; 2012 Oct; 32(5):593-601. PubMed ID: 22926591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response to fluvoxamine augmentation for obsessive and compulsive symptoms in schizophrenia.
    Dwivedi S; Pavuluri M; Heidenreich J; Wright T
    J Child Adolesc Psychopharmacol; 2002; 12(1):69-70. PubMed ID: 12014598
    [No Abstract]   [Full Text] [Related]  

  • 5. The difference between the formal and the functional dose: the case of the patient on thioridazine and fluvoxamine.
    Preskorn SH
    J Psychiatr Pract; 2005 May; 11(3):192-6. PubMed ID: 15920392
    [No Abstract]   [Full Text] [Related]  

  • 6. Successful treatment of Meige's syndrome induced by risperidone and fluvoxamine with olanzapine monotherapy in schizophrenia.
    Miyamoto S; Miyake N; Ogino S; Endo T; Yamaguchi N
    Psychiatry Clin Neurosci; 2007 Dec; 61(6):702-3. PubMed ID: 18081639
    [No Abstract]   [Full Text] [Related]  

  • 7. Melatonin secretion during fluvoxamine treatment in medicated chronic schizophrenic patients: evidence for the development of tolerance to selective serotonin re-uptake inhibitor.
    Silver H; Barash I; Odnopozov N; Jahjah N; Mizruhin A
    Biol Psychiatry; 1996 Jul; 40(1):75-7. PubMed ID: 8780859
    [No Abstract]   [Full Text] [Related]  

  • 8. Add-on fluvoxamine and negative symptoms of schizophrenia: analysis of data from augmentation studies in a single center.
    Silver H; Bilker WB
    J Clin Psychopharmacol; 2013 Oct; 33(5):710-1. PubMed ID: 23899641
    [No Abstract]   [Full Text] [Related]  

  • 9.
    Boyle K; Cornett S; Fijtman A; Hunt-Harrison T
    J Child Adolesc Psychopharmacol; 2021 Sep; 31(7):514-515. PubMed ID: 34166111
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical impact of fluvoxamine-mediated long QTU syndrome.
    Nia AM; Dahlem KM; Gassanov N; Hungerbühler H; Fuhr U; Er F
    Eur J Clin Pharmacol; 2012 Jan; 68(1):109-11. PubMed ID: 21713517
    [No Abstract]   [Full Text] [Related]  

  • 11. Effects of adjunctive fluvoxamine on metabolic parameters and psychopathology in clozapine-treated patients with schizophrenia: A 12-week, randomized, double-blind, placebo-controlled study.
    Lu ML; Chen TT; Kuo PH; Hsu CC; Chen CH
    Schizophr Res; 2018 Mar; 193():126-133. PubMed ID: 28688742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluvoxamine augmentation in risperidone-resistant schizophrenia: an open trial.
    Takahashi H; Sugita T; Higuchi H; Shimizu T
    Hum Psychopharmacol; 2002 Mar; 17(2):95-8. PubMed ID: 12404698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Augmentation with fluvoxamine but not maprotiline improves negative symptoms in treated schizophrenia: evidence for a specific serotonergic effect from a double-blind study.
    Silver H; Shmugliakov N
    J Clin Psychopharmacol; 1998 Jun; 18(3):208-11. PubMed ID: 9617979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: differential effects of fluvoxamine and paroxetine in a prospective study.
    Wetzel H; Anghelescu I; Szegedi A; Wiesner J; Weigmann H; Härter S; Hiemke C
    J Clin Psychopharmacol; 1998 Feb; 18(1):2-9. PubMed ID: 9472836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The involvement of BDNF-CREB signaling pathways in the pharmacological mechanism of combined SSRI- antipsychotic treatment in schizophrenia.
    Einoch R; Weinreb O; Mandiuk N; Youdim MBH; Bilker W; Silver H
    Eur Neuropsychopharmacol; 2017 May; 27(5):470-483. PubMed ID: 28410959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [SSRI antidepressants and negative schizophrenic symptoms: differences between paroxetine and fluvoxamine in patients treated with olanzapine].
    Rusconi AC; Carlone C; Muscillo M; Coccanari de' Fornari MA; Podda L; Piccione M
    Riv Psichiatr; 2009; 44(5):313-9. PubMed ID: 20066819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patients with obsessive-compulsive disorder (OCD) displayed cognitive deficits consistent with a dysfunction of the dorsolateral-striatal circuit.
    Fontenelle LF; Mendlowicz MV; Versiani M
    Psychol Med; 2004 Oct; 34(7):1367-8; author reply 1368-9. PubMed ID: 15697063
    [No Abstract]   [Full Text] [Related]  

  • 18. Fluvoxamine augmentation of olanzapine in chronic schizophrenia: pharmacokinetic interactions and clinical effects.
    Hiemke C; Peled A; Jabarin M; Hadjez J; Weigmann H; Härtter S; Modai I; Ritsner M; Silver H
    J Clin Psychopharmacol; 2002 Oct; 22(5):502-6. PubMed ID: 12352274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of kleptomania with fluvoxamine.
    Chong SA; Low BL
    Acta Psychiatr Scand; 1996 Apr; 93(4):314-5. PubMed ID: 8712034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Olanzapine plus fluvoxamine and olanzapine alone for the treatment of an acute exacerbation of schizophrenia.
    Chaichan W
    Psychiatry Clin Neurosci; 2004 Aug; 58(4):364-8. PubMed ID: 15298648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.